Large cell/neuroendocrine carcinoma
Russell Gollard1, Sejal Jhatakia, Max Elliott
1Cancer & Blood Specialists of Nevada, 58 N. Pecos Road, Henderson, NV 89074, USA. rgollard@hotmail.com
Lung Cancer (Amsterdam, Netherlands)
|February 6, 2010
Summary
Large cell neuroendocrine tumors (LCNEC) of the lung are a distinct cancer subtype. Research suggests multi-modality therapy may offer the most promising treatment approach for LCNEC.
Area of Science:
- Oncology
- Pulmonology
- Pathology
Background:
- Large cell neuroendocrine tumors (LCNEC) of the lung are a recently reclassified subtype of lung cancer.
- LCNEC exhibits features overlapping both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To review the diagnostic challenges associated with LCNEC.
- To describe the typical clinical presentations and natural history of LCNEC.
- To analyze existing treatment data for LCNEC.
Main Methods:
- Literature review of diagnostic criteria for LCNEC.
- Analysis of reported clinical presentations and disease progression.
- Review of treatment outcomes from various therapeutic modalities.
Main Results:
- Diagnostic difficulties are common due to overlapping features with SCLC and NSCLC.
- Understanding the natural history is crucial for effective management.
- Limited but emerging data on treatment efficacy.
Conclusions:
- Multi-modality therapy, similar to other lung cancer types, is suggested as a promising treatment strategy for LCNEC.
- Further research is needed to optimize therapeutic protocols for LCNEC.
- Accurate diagnosis and understanding of LCNEC's behavior are key to improving patient outcomes.
